Focal Segmental Glomerulosclerosis
📧 Sign up to get email alerts when something new happens for Focal Segmental Glomerulosclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-11Clinical Trial Update: Obinutuzumab in Primary FSGS [Phase 2]
A Phase 2 trial evaluating obinutuzumab for primary focal segmental glomerulosclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant [EARLY_Phase 1]
This update reports the completion of an early-phase trial assessing preemptive rituximab to prevent recurrence of focal segmental glomerulo…
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: Atrasentan in Patients With Proteinuric Glomerular Diseases [Phase 2]
Phase 2 trial of atrasentan for proteinuric glomerular diseases is active but not recruiting, including IgA nephropathy, Focal segmental glo…
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
A clinical trial update from Assistance Publique - Hôpitaux de Paris describes a study on epithelial dysmetabolism and renal fibrosis in ANC…
-
CLINICAL_TRIALS research · 2025-05-11Clinical Trial Update: Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
An observational study at the University of Michigan is evaluating recurrence after kidney transplantation in patients with focal segmental …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-05-06Clinical Trial Update: Rituximab Treatment of Focal Segmental Glomerulosclerosis [Phase 2]
Phase 2 trial of rituximab for focal segmental glomerulosclerosis has been withdrawn.
-
CLINICAL_TRIALS research · 2025-04-30Clinical Trial Update: Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children [NA]
Post-approval study for the Liposorber LA-15 System in children with focal segmental glomerulosclerosis is currently recruiting.
-
CLINICAL_TRIALS research · 2025-04-24Clinical Trial Update: Nephrotic Syndrome Study Network
Clinical trial update from the Nephrotic Syndrome Study Network indicating that the study is currently recruiting for conditions including M…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment [Phase 1]
This completed Phase 1 study evaluated the pharmacokinetics and safety of Inaxaplin in participants with mild or moderate hepatic impairment…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Raman Spectroscopy Diagnosis of Kidney Diseases
This update describes an ongoing clinical trial evaluating Raman spectroscopy as a diagnostic tool for kidney diseases, including IgA nephro…
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
ClinicalTrials.gov update describes a study on genetic causes of focal segmental glomerulosclerosis, nephrotic syndrome, and related kidney …
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease [Phase 2]
A Phase 2 clinical trial evaluating tumor necrosis factor inhibition for focal segmental glomerulosclerosis and treatment-resistant minimal …
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System [NA]
An update on a post-approval clinical study evaluating the LIPOSORBER LA-15 lipoprotein apheresis system for drug-resistant adult and pediat…
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects [Phase 1]
First-in-human Phase 1 trial to evaluate safety, tolerability, and pharmacology of HS-10390 in healthy subjects; the study lists IgA nephrop…
-
FDA label_change · 2024-09-05FDA Approved: FILSPARI — Supplemental Application (Travere Therapeutics, Inc.)
FDA approved a supplemental application for FILSPARI (sparsentan) submitted by Travere Therapeutics, Inc., relating to changes or expansion …
-
CLINICAL_TRIALS research · 2024-06-05Clinical Trial Update: Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1
Clinical trial update investigating predictive determinants of nephrotic syndrome remission in patients with at-risk APOL1 polymorphisms, in…
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) [Phase 3]
A Phase 3 study evaluating sparsentan for primary focal segmental glomerulosclerosis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) [Phase 2]
Phase 2 trial of PF-06730512 in adults with focal segmental glomerulosclerosis (FSGS) was terminated; results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome [Phase 2]
Phase 2 study of CCX140-B in subjects with primary FSGS and nephrotic syndrome was terminated. Results have been posted on 2024-02-06.
-
CLINICAL_TRIALS trial_result · 2023-12-05Clinical Trial Update: A Study of CCX140-B in Subjects With FSGS [Phase 2]
Phase 2 trial of CCX140-B in subjects with focal segmental glomerulosclerosis has completed, with results posted in December 2023.
-
CLINICAL_TRIALS trial_result · 2023-07-10Clinical Trial Update: Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis [Phase 2]
Phase 2a trial of VX-147 in adults with APOL1-mediated focal segmental glomerulosclerosis has completed, and results were posted in July 202…
-
FDA approval · 2023-02-17FDA Approved: FILSPARI — Original Application (Travere Therapeutics, Inc.)
FDA grants original approval for FILSPARI (sparsentan) from Travere Therapeutics for the treatment of focal segmental glomerulosclerosis.
-
CLINICAL_TRIALS trial_result · 2022-07-29Clinical Trial Update: Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan [Phase 2]
Phase 2 clinical trial evaluating safety and effectiveness of propagermanium in patients with focal segmental glomerulosclerosis receiving i…
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX [Phase 2]
Phase 2 trial evaluating bardoxolone methyl in rare chronic kidney diseases has completed, with results posted January 18, 2022. Diseases st…
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients [Phase 2]
Phase 2 trial evaluating Bleselumab for preventing recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients …